SEC Form 4 · accession 0001209191-19-011483
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carman Alenson
Officer — Principal Accounting Officer
Period of report
Sep 28, 2018
Accepted (ET)
Feb 20, 2019 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Sep 28, 2018 | S | 152 | $76.45 | D | 0 | D | |
| Common stockF2 | Feb 16, 2019 | M | 790 | — | A | 790 | D | |
| Common stock | Feb 19, 2019 | F | 278 | $58.03 | D | 512 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted stock unitsF2,F3 | — | Feb 16, 2019 | M | 790 | D | — | — | Common stock | 790 | 1,580 | D |
Explanation of responses
- F1The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.44 to $76.47. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F2Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F3The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.